Pal-GHK + Pal-GQPR Combination
Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
Matrixyl 3000 is not a single peptide but a combination of two cosmetic peptides in one product — one that stimulates collagen production and one that reduces skin inflammation. Developed as a successor to the original Matrixyl, it is widely used in anti-ageing skincare products. It has no pharmaceutical approval.
No published studies found on PubMed.
Matrixyl 3000 has no pharmaceutical authorisation. It is widely used as a cosmetic ingredient. Small studies report wrinkle reduction, with a head-to-head comparison against the original Matrixyl suggesting greater statistical significance on wrinkle endpoints.
As a two-component combination, Matrixyl 3000's evidence should be interpreted alongside the individual component entries: Palmitoyl Tripeptide-1 (#139) and Palmitoyl Tetrapeptide-7 (#140). It is a topical cosmetic ingredient.
Research suggests the two components work through complementary mechanisms: Pal-GHK stimulates collagen and extracellular matrix production (pro-repair), while Pal-GQPR suppresses inflammatory signalling (anti-inflammatory). The rationale for combining them is that both matrix degradation and chronic low-grade inflammation contribute to skin ageing.
Research suggests small studies (24-39 participants) show wrinkle reduction, with a comparison against the original Matrixyl suggesting improved results. The combination rationale — addressing both collagen loss and inflammation simultaneously — is biologically plausible. All published data originate from the manufacturer. No large independent trials exist. It is not possible to determine from the combination studies which component is responsible for the observed effects. It is a topical cosmetic ingredient.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
Epitalon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. Animal lifespan studies in mice reported by the Khavinson group form the core evidence base. The telomerase activation claims are based on in vitro studies and mouse models from a single research programme. Independent replication of the key findings has not been published. The relationship between in vitro telomerase activation and any clinical outcome in humans is not established. Products available through unregulated channels lack pharmaceutical quality assurance.
FOXO4-DRI has no marketing authorisation. No human clinical trials have been conducted. The evidence comes from a single high-profile publication (Cell, 2017) demonstrating effects in three mouse models. The senolytic field is an active area of pharmaceutical research, but FOXO4-DRI faces significant challenges for clinical translation, including its large size (46 amino acids), manufacturing complexity, and the absence of human pharmacokinetic or safety data. Products available through unregulated channels — which would need to reliably synthesise a 46-amino-acid all-D-amino-acid peptide — face exceptional quality assurance challenges.
